BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29057117)

  • 21. Randomized Multicenter Clinical Trial Comparing 0.1% Brimonidine/0.5% Timolol Versus 1% Dorzolamide/0.5% Timolol as Adjuncts to Prostaglandin Analogues: Aibeta Crossover Study.
    Inatani M; Orii Y; Iwasaki K; Arimura S; Sunagawa H; Shiokawa M; Inoue K; Sakono T; Sakono T; Kuwamura R; Yoshida A; Oi J; Kuwayama Y; Kano K; Kido N; Matsuyama A; Ozaki M; Abe H; Inoue C; Nakagawa S; Musashi K; Kanamori A; Lee J; Otani S; Aoki R; Tanabe H; Nakakura S; Suzuki K; Sagara T; Saito Y; Sameshima M; Urahashi M; Watanabe-Kitamura F; Inoue T; Kagaya F; Murai Y; Mori S; Ueda K; Kurimoto T; Yamada-Nakanishi Y; Nakamura M; Yamashita T; Ishiyama S; Manabe S; Takaki K; Hayashi K; Ishida A; Tsutsui A; Manabe K; Tanito M
    Adv Ther; 2023 Sep; 40(9):4074-4092. PubMed ID: 37452961
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure.
    Sherwood M; Brandt J;
    Surv Ophthalmol; 2001 May; 45 Suppl 4():S361-8. PubMed ID: 11434939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials.
    Myers JS; Vold S; Zaman F; Williams JM; Hollander DA
    Clin Ophthalmol; 2014; 8():643-52. PubMed ID: 24707169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure.
    Arcieri ES; Arcieri RS; Pereira AC; Andreo EG; Finotti IG; Sá Filho WF
    Curr Med Res Opin; 2007 Apr; 23(4):683-9. PubMed ID: 17407624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension.
    Goni FJ
    Eur J Ophthalmol; 2005 Sep - Oct 2005; 15(5):581-590. PubMed ID: 28221460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of patients with primary open-angle glaucoma with a fixed combination of brimonidine 0.2%/timolol 0.5%: multicenter, open-label, observational study in Germany.
    Thelen U; Buchholz P; Kimmich F
    Curr Med Res Opin; 2009 Apr; 25(4):1003-9. PubMed ID: 19275517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraocular Peak Pressure in Patients Under Treatment With Fixed Combination of Bimatoprost/Timolol/Brimonidine Once Daily Versus Twice Daily.
    Susanna BN; Susanna CN; Susanna FN; Mota RT; Barbosa GCS; Lima VL; Susanna R
    J Glaucoma; 2022 Oct; 31(10):e96-e100. PubMed ID: 35513899
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the Intraocular Pressure-Lowering Efficacy and Safety of the Brinzolamide/Brimonidine Fixed-Dose Combination versus Concomitant Use of Brinzolamide and Brimonidine for Management of Open-Angle Glaucoma or Ocular Hypertension.
    Wang N; Lu DW; Pan Y; Astakhov Y; Iureva T; Adewale A; Walker TM
    Clin Ophthalmol; 2020; 14():221-230. PubMed ID: 32158181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study.
    Feuerhake C; Buchholz P; Kimmich F
    Curr Med Res Opin; 2009 Apr; 25(4):1037-43. PubMed ID: 19290780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of ocular hypotensive actions of fixed combinations of brimonidine/timolol and dorzolamide/timolol.
    García-Feijoó J; Sáenz-Francés F; Martínez-de-la-Casa JM; Méndez-Hernández C; Fernández-Vidal A; Calvo-González C; García-Sánchez J
    Curr Med Res Opin; 2010 Jul; 26(7):1599-606. PubMed ID: 20429818
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension.
    Lerner SF; Oddone F; Lu DW; Sanseau A; Guarro M; Ridolfi A; Hubatsch D
    Clin Ophthalmol; 2019; 13():2411-2419. PubMed ID: 31824135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the effects of bimatoprost and a fixed combination of latanoprost and timolol on circadian intraocular pressure.
    Rossetti L; Karabatsas CH; Topouzis F; Vetrugno M; Centofanti M; Boehm A; Viswanathan A; Vorwerk C; Goldblum D
    Ophthalmology; 2007 Dec; 114(12):2244-51. PubMed ID: 17459480
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma.
    Cho SW; Kim JM; Park KH; Choi CY
    Jpn J Ophthalmol; 2010 Sep; 54(5):407-13. PubMed ID: 21052902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma.
    Martinez A; Sanchez M
    Curr Med Res Opin; 2007 May; 23(5):1025-32. PubMed ID: 17519068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 3-month randomized controlled trial of bimatoprost (LUMIGAN) versus combined timolol and dorzolamide (Cosopt) in patients with glaucoma or ocular hypertension.
    Coleman AL; Lerner F; Bernstein P; Whitcup SM
    Ophthalmology; 2003 Dec; 110(12):2362-8. PubMed ID: 14644719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1).
    Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
    Ophthalmology; 2020 Dec; 127(12):1627-1641. PubMed ID: 32544560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy.
    Schnober D; Hubatsch DA; Scherzer ML
    Clin Ophthalmol; 2015; 9():825-32. PubMed ID: 26005326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dorzolamide/Timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures.
    Solish AM; DeLucca PT; Cassel DA; Kolodny AH; Hustad CM; Skobieranda F
    J Glaucoma; 2004 Apr; 13(2):149-57. PubMed ID: 15097262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.